UY37759A - Compuestos y composiciones para inducir condrogénesis - Google Patents

Compuestos y composiciones para inducir condrogénesis

Info

Publication number
UY37759A
UY37759A UY0001037759A UY37759A UY37759A UY 37759 A UY37759 A UY 37759A UY 0001037759 A UY0001037759 A UY 0001037759A UY 37759 A UY37759 A UY 37759A UY 37759 A UY37759 A UY 37759A
Authority
UY
Uruguay
Prior art keywords
compounds
induce
compositions
condrogenesis
pharmaceutically acceptable
Prior art date
Application number
UY0001037759A
Other languages
English (en)
Inventor
Choi Ha-Soon
Paul LAJINESS James
Jiqing Jiang
Zhicheng Wang
Bao Nguyen
Michael James Petrassi Hank
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37759A publication Critical patent/UY37759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo o una sal farmacéuticamente aceptable, tautómero, o estereoisómero, del mismo, donde las variables son como se definen en este documento. La presente invención proporciona además composiciones farmacéuticas que comprenden tales compuestos; y métodos para usar tales compuestos para tratar lesiones o daños en las articulaciones en un mamífero, para inducir la producción de cartílago hialino o para inducir la diferenciación de células progenitoras condrogénicas en condrocitos maduros.
UY0001037759A 2017-06-09 2018-06-05 Compuestos y composiciones para inducir condrogénesis UY37759A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09

Publications (1)

Publication Number Publication Date
UY37759A true UY37759A (es) 2019-01-31

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037759A UY37759A (es) 2017-06-09 2018-06-05 Compuestos y composiciones para inducir condrogénesis

Country Status (37)

Country Link
US (3) US11091499B2 (es)
EP (3) EP3634967A1 (es)
JP (2) JP7229945B2 (es)
KR (1) KR102656524B1 (es)
CN (1) CN110719913B (es)
AR (1) AR113227A1 (es)
AU (1) AU2018279306C1 (es)
BR (1) BR112019025866A2 (es)
CA (1) CA3063985A1 (es)
CL (1) CL2019003564A1 (es)
CO (1) CO2019013706A2 (es)
CR (1) CR20190551A (es)
CU (1) CU24577B1 (es)
DK (1) DK3915994T3 (es)
DO (1) DOP2019000305A (es)
EA (1) EA201992858A1 (es)
EC (1) ECSP19086712A (es)
ES (1) ES2971319T3 (es)
FI (1) FI3915994T3 (es)
HR (1) HRP20240155T1 (es)
HU (1) HUE065194T2 (es)
IL (2) IL300755A (es)
JO (1) JOP20190282A1 (es)
LT (1) LT3915994T (es)
MA (2) MA50547A (es)
MX (1) MX2019014757A (es)
PE (1) PE20200403A1 (es)
PH (1) PH12019502764A1 (es)
PL (1) PL3915994T3 (es)
PT (1) PT3915994T (es)
RS (1) RS65161B1 (es)
SA (1) SA519410729B1 (es)
SI (1) SI3915994T1 (es)
TW (1) TWI782036B (es)
UY (1) UY37759A (es)
WO (1) WO2018225009A1 (es)
ZA (1) ZA201907358B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
EP3891154B1 (en) * 2018-12-06 2023-08-16 Novartis AG 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
WO2008008884A2 (en) 2006-07-12 2008-01-17 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2757480A1 (en) 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
KR20160015403A (ko) 2009-07-14 2016-02-12 더 스크립스 리서치 인스티튜트 중간엽 줄기 세포 분화
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
KR102283996B1 (ko) * 2013-03-15 2021-07-29 더 스크립스 리서치 인스티튜트 연골형성의 유도를 위한 화합물 및 방법
AU2015259403B2 (en) * 2014-05-13 2017-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف

Also Published As

Publication number Publication date
US11753416B2 (en) 2023-09-12
LT3915994T (lt) 2024-02-26
KR102656524B1 (ko) 2024-04-12
IL300755A (en) 2023-04-01
CU24577B1 (es) 2022-02-04
PH12019502764A1 (en) 2020-07-13
MA57022B1 (fr) 2024-02-29
CA3063985A1 (en) 2018-12-13
MA50547A (fr) 2020-09-16
HUE065194T2 (hu) 2024-05-28
EP3634967A1 (en) 2020-04-15
RU2019144107A (ru) 2021-07-09
JP7432778B2 (ja) 2024-02-16
WO2018225009A1 (en) 2018-12-13
TWI782036B (zh) 2022-11-01
DOP2019000305A (es) 2019-01-15
JP7229945B2 (ja) 2023-02-28
IL271154B2 (en) 2023-07-01
IL271154B1 (en) 2023-03-01
JOP20190282A1 (ar) 2019-12-05
JP2020522550A (ja) 2020-07-30
JP2023062064A (ja) 2023-05-02
CU20190098A7 (es) 2020-10-20
PT3915994T (pt) 2024-02-15
HRP20240155T1 (hr) 2024-04-12
AU2018279306B2 (en) 2020-07-09
ES2971319T3 (es) 2024-06-04
PL3915994T3 (pl) 2024-05-20
US20210079010A1 (en) 2021-03-18
KR20200013046A (ko) 2020-02-05
CN110719913B (zh) 2022-10-28
RU2019144107A3 (es) 2021-07-30
US20230365580A1 (en) 2023-11-16
US20210347784A1 (en) 2021-11-11
SA519410729B1 (ar) 2022-07-03
CL2019003564A1 (es) 2020-06-19
EP3915994A1 (en) 2021-12-01
AU2018279306C1 (en) 2021-01-14
MX2019014757A (es) 2020-02-12
FI3915994T3 (fi) 2024-02-14
CO2019013706A2 (es) 2020-04-01
CR20190551A (es) 2020-01-28
ZA201907358B (en) 2022-04-28
RS65161B1 (sr) 2024-02-29
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (en) 2023-11-22
EP3915994B9 (en) 2024-02-28
BR112019025866A2 (pt) 2020-07-14
IL271154A (en) 2020-01-30
TW201902900A (zh) 2019-01-16
SI3915994T1 (sl) 2024-03-29
ECSP19086712A (es) 2019-12-27
AU2018279306A1 (en) 2019-12-05
NZ759434A (en) 2024-01-26
DK3915994T3 (da) 2024-02-19
US11091499B2 (en) 2021-08-17
EP4299123A2 (en) 2024-01-03
AR113227A1 (es) 2020-02-19
PE20200403A1 (es) 2020-02-26
CN110719913A (zh) 2020-01-21
EP4299123A3 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
CR20160528A (es) Compuestos y composiciones para inducir condrogénesis
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
UY37759A (es) Compuestos y composiciones para inducir condrogénesis
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
AR085668A1 (es) Terapias combinadas para malignidades hematologicas
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
ECSP14013157A (es) Formulaciones liofilizadas de fgf-18
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
WO2016048861A3 (en) Heterocyclic compounds and use thereof
UY33019A (es) Nuevos derivados de 2-aminotiadiazol
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
PA8768201A1 (es) Composiciones farmacéuticas que contienen derivados de ácido indol sustituidos como inhibidores del inhibidor del activador de plasminógeno 1 (pai-1)
AR094662A1 (es) Compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias